title: Stroma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressure.
abstract: We examined the effect of a nitric oxide (NO) quencher, stroma-free human hemoglobin A (HbA0; 0.01, 0.05, 0.1, 0.2 g/kg), on the blood flow measured using the Doppler flow technique, tumor oxygen pressure (pO2) and the diameter of the arterioles using R3230Ac mammary adenocarcinoma as the tumor model. In female Fischer 344 rats with 1-cm-diameter tumors implanted in the lateral aspect of the left quadriceps, intravenous infusion of 0.1 and 0.2 g/kg HbA0 decreased both central tumor and peripheral tumor blood flow by 20-30% (P < 0.05). Tumor pO2 decreased 28% with 0.2 g/kg HbA0, from 15 mm Hg (baseline) to 11 mm Hg at 10 min (P = 0.02). Although 0.2 g/kg HbA0 increased blood flow 55% in the left quadriceps muscle proximal to the implanted tumor (P < 0.05), HbA0 had little effect on blood flow in right quadriceps muscle with no tumor implanted, and increased right quadriceps pO2, from 21 mm Hg (baseline) to 23 mm Hg at 10 min (P = 0.03). HbA0 increased mean arterial pressure 5-10% in a manner that was dependent on dose while heart rate concurrently decreased 9-19%. The diameter of the arterioles supplying the tumor was rapidly reduced 10% by 0.2 g/kg HbA0 (P = 0.037) and remained stable through 60 min of observation (P = 0.005). HbA0 selectively reduces tumor blood flow and tumor pO2 through vasoconstriction of the arterioles supplying the tumor. Vascular NO quenching provides an alternative to NO synthase inhibition as a means to achieve the goal of selective tumor hypoxia.
authors.affiliation: Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Hahn
authors.forename: R D
authors.initials: RD
authors.lastname: Braun
authors.forename: M W
authors.initials: MW
authors.lastname: Dewhirst
authors.forename: S
authors.initials: S
authors.lastname: Shan
authors.forename: S A
authors.initials: SA
authors.lastname: Snyder
authors.forename: J M
authors.initials: JM
authors.lastname: Taube
authors.forename: E T
authors.initials: ET
authors.lastname: Ong
authors.forename: G L
authors.initials: GL
authors.lastname: Rosner
authors.forename: R K
authors.initials: RK
authors.lastname: Dodge
authors.forename: J
authors.initials: J
authors.lastname: Bonaventura
authors.forename: C
authors.initials: C
authors.lastname: Bonaventura
authors.forename: J
authors.initials: J
authors.lastname: DeAngelo
authors.forename: R E
authors.initials: RE
authors.lastname: Meyer
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply* / Q000503:physiopathology; D000818:Animals; D001160:Arterioles / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D015687:Cell Hypoxia; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006441:Hemoglobin A / Q000494:pharmacology*; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply* / Q000503:physiopathology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors*; D010100:Oxygen / Q000378:metabolism* / Q000494:pharmacology; D010313:Partial Pressure; D051381:Rats; D011916:Rats, Inbred F344; D012039:Regional Blood Flow / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects*
chemical_list: D009569:Nitric Oxide; D006441:Hemoglobin A; D010100:Oxygen